Navigation Links
MultiCell Technologies Relocates Corporate Headquarters
Date:5/2/2008

WOONSOCKET, R.I., May 2 /PRNewswire-FirstCall/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET) has moved into new space and will have a different address and telephone numbers. Effective May 1, 2008:

-- the new address is: 68 Cumberland Street, Suite 301, Woonsocket,

RI 02895.

-- new phone number is: (401) 762-0045

-- the new fax number is: (401) 762-0098

MultiCell Technologies, Inc. is a biopharmaceutical company developing new therapeutics including:

MCT-125 for the treatment of primary fatigue in MS patients.

MCT-175 for the treatment of relapsing-remitting MS.

MCT-465 for the treatment of TLR3 positive breast cancers.

MCT-475 for the treatment of TLR3 positive cervical cancers.

MultiCell also sells and/or licenses immortalized human liver cells to the pharmaceutical industry and holds patents on the Sybiol(R) synthetic bio-liver device and liver-derived adult human stem cells.

For more information about MultiCell Technologies, please visit http://www.multicelltech.com .

Caution Regarding Forward-Looking Statements

Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," "forecast," "could," and "would." Examples of such forward looking statements include statements regarding the timing, design, scope, and anticipated results of our clinical development programs. MultiCell bases these forward- looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-KSB for the fiscal year ended November 30, 2007, and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and each assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.


'/>"/>
SOURCE MultiCell Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
2. MultiCell Technologies To Increase Focus on Therapeutic Candidates
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
7. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
8. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
9. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
10. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
11. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published ... the peer-reviewed journal from touchONCOLOGY, Andrew D ... cost of cancer care is placing an increasing ... of expensive biologic therapies. With the patents on ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
(Date:6/23/2016)... ... 2016 , ... Velocity Products, a division of Morris Group, ... exclusively for Okuma CNC machining centers at The International Manufacturing Technology Show, IMTS, ... companies with expertise in toolholding, cutting tools, machining dynamics and distribution, Velocity SMART ...
(Date:6/23/2016)... , June 23, 2016 ... market research report to its pharmaceuticals section with ... product details and much more. Complete ... across 151 pages, profiling 15 companies and supported ... at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The ...
Breaking Biology Technology:
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
Breaking Biology News(10 mins):